Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,846,720
  • Shares Outstanding, K 181,164
  • Annual Sales, $ 2,176 M
  • Annual Income, $ 613,670 K
  • 60-Month Beta 0.96
  • Price/Sales 12.70
  • Price/Cash Flow 41.48
  • Price/Book 7.84
Trade SGEN with:

Options Overview

Details
  • Implied Volatility 49.38%
  • Historical Volatility 63.89%
  • IV Percentile 75%
  • IV Rank 26.96%
  • IV High 137.27% on 03/16/20
  • IV Low 28.48% on 09/09/20
  • Put/Call Vol Ratio 0.78
  • Today's Volume 176
  • Volume Avg (30-Day) 1,564
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 5,583
  • Open Int (30-Day) 11,254

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.59
  • Number of Estimates 8
  • High Estimate -0.50
  • Low Estimate -0.66
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +7.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.90 +1.36%
on 03/03/21
199.00 -25.18%
on 02/05/21
-14.21 (-8.71%)
since 02/03/21
3-Month
146.90 +1.36%
on 03/03/21
202.60 -26.51%
on 12/18/20
-31.26 (-17.35%)
since 12/03/20
52-Week
90.57 +64.40%
on 03/16/20
213.94 -30.40%
on 10/13/20
+41.50 (+38.64%)
since 03/03/20

Most Recent Stories

More News
Seagen to Present at the Cowen 41st Annual Healthcare Conference

Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The presentation...

SGEN : 149.75 (-2.58%)
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer

Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

ACOR : 6.24 (+0.81%)
SGEN : 149.75 (-2.58%)
CLSD : 3.39 (-0.59%)
AVIR : 71.85 (+0.04%)
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

TOKYO and , /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:  , Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics...

ALPMY : 16.2065 (+0.79%)
SGEN : 149.75 (-2.58%)
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV(R) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of submissions for two supplemental Biologics License Applications...

SGEN : 149.75 (-2.58%)
Stock Market News for Feb 17, 2021

The Dow booked a second straight record high on Tuesday with progress in Biden???s $1.9 trillion coronavirus relief package and data showing COVID-19 cases dropping.

LUV : 58.27 (+0.80%)
BA : 235.25 (+5.43%)
GILD : 63.12 (+0.17%)
CRM : 208.14 (-2.50%)
SGEN : 149.75 (-2.58%)
NTES : 108.20 (-1.75%)
PTON : 109.78 (-6.94%)
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

and , /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:  , Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced results from the second cohort (cohort 2) of patients in...

ALPMY : 16.2065 (+0.79%)
SGEN : 149.75 (-2.58%)
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

and , /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: , Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV...

ALPMF : 15.7800 (+0.13%)
ALPMY : 16.2065 (+0.79%)
SGEN : 149.75 (-2.58%)
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV(R) (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

--- EV-301 Intended to Support Global Registrations, Convert Accelerated to Regular Approval in U.S. -

SGEN : 149.75 (-2.58%)
Seagen and Astellas Announce Presentation of Results from PADCEV(R) (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy

--- Data Presented in Oral Presentation at the 2021 ASCO Genitourinary Cancers Symposium -

SGEN : 149.75 (-2.58%)
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

RHHBY : 40.5200 (-1.29%)
MRK : 73.12 (+0.37%)
SGEN : 149.75 (-2.58%)
TAK : 17.65 (+2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.

See More

Key Turning Points

3rd Resistance Point 159.05
2nd Resistance Point 157.02
1st Resistance Point 155.36
Last Price 150.20
1st Support Level 151.67
2nd Support Level 149.64
3rd Support Level 147.98

See More

52-Week High 213.94
Fibonacci 61.8% 166.81
Fibonacci 50% 152.26
Last Price 150.20
Fibonacci 38.2% 137.70
52-Week Low 90.57

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar